Top Suppliers:I want be here
Related CAS#:
760176-26-9 79517-01-4
622838-44-2 83150-76-9
226084-96-4 848820-27-9
204318-14-9 147790-89-4
1134880-79-7 135467-16-2

83150-76-9

83150-76-9 structure
83150-76-9 structure
  • Name: Octreotide acetate
  • Chemical Name: Octreotide acetate
  • CAS Number: 83150-76-9
  • Molecular Formula: C49H66N10O10S2
  • Molecular Weight: 1019.239
  • Catalog: Biochemical Peptide
  • Create Date: 2018-07-12 12:30:52
  • Modify Date: 2024-01-02 15:56:33
  • Octreotide is a somatostatin analog that binds to the somatostatin receptor, mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production.
Name Octreotide acetate
Synonyms Octreotode Acetate
Octreotide
Sandostatin<*>
SMS 201-995
OCTREOTIDE ACETATE (GMP)
Octreotideacetate
1,2-Dithia-5,8,11,14,17-pentaazacycloeicosane-4-carboxamide, 10-(4-aminobutyl)-19-[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]-7-[(1R)-1-hydroxyethyl]-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-16-(phenylmethyl)-, (4R,7S,10S,13R,16S,19R)-
ctreotide
H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol acetate salt (Disulfide bond)
MFCD00871400
D-Phe-Cys(1)-Phe-D-Trp-Lys-Thr-Cys(1)-N-[(1R,2R)-1-(Hydroxymethyl)-2-hydroxypropyl]-NH2
Phe-c(Cys-Phe-Trp-Lys-Thr-Cys)-CH(CH2OH)-CH(OH)-CH3
Longastatin
OXTREOTIDE
(4R,7S,10S,13R,16S,19R)-10-(4-Aminobutyl)-16-benzyl-N-[(2R,3R)-1,3-dihydroxy-2-butanyl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-19-(D-phenylalanylamino)-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide
DARAMONOL
Sandostatin
Ocetreotide,Acetate
Description Octreotide is a somatostatin analog that binds to the somatostatin receptor, mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production.
Related Catalog
In Vitro Octreotide reverses the PA-induced alterations in Akt and GSK3β phosphorylation and expression of GS mRNA in HepG2 cells[1].
In Vivo Octreotide significantly lowers the plasma glucose levels in the obese rats of the HFD group. Octreotide intervention significantly decreases the serum insulin concentration; however, there is no marked reduction in serum TG, TC, FFA, ALT and AST levels. Octreotide significantly inhibits the HOMA index. Octreotide decreases ipGTT and ipITT AUCs, but not significantly. Octreotide improves fat degeneration in rats with HFD-induced obesity and lipid droplet accumulation in PA-treated HepG2 cells. Octreotide promotes the phosphorylation of Akt and GSK3β and the expression of GS mRNA in rats with HFD-induced obesity[1]. Octreotide reduces body weight and wet kidney weight compared with the vehicle-treated (CONT) group. PAS and Octreotide/PAS treatment decrease cAMP levels, but Octreotide alone does not in PCK rats. In the Octreotide/PAS group, there are a significantly fewer pS6-positive cells than in the PAS alone group[2].
Animal Admin AMale PCK rats (n = 24) are assigned randomly to 1 of 4 groups (n = 6 per group): treatment by subcutaneous injection every 4 weeks treatment with 8 mg/kg Octreotide-LAR alone, 8 mg/kg PAS-LAR alone, co-application of 8 mg/kg Octreotide and 8 mg/kg PAS, or vehicle (microparticles liquid; CONT) from 4 to 16 weeks of age. The vehicle contains copolymer microparticles with polylactic-co-glycolic acid (PLGA). In 4- and 15-week-old conscious rats, heart rate (HR), diastolic blood pressure (DBP), and systolic blood pressure (SBP) are determined using a tail-cuff sphygmomanometer. Twenty-four-hour urine volume and food consumption are measured using metabolic cages after 15.5 weeks of age. After body weight measurement, the animals are anesthetized with sodium pentobarbital at 16 weeks of age, and the kidneys and liver are removed rapidly, causing lethal exsanguination. Total wet kidney weight and wet liver weight are measured, and blood samples are collected for measurements of serum urea nitrogen (SUN), aspartate amino transferase (AST), alanine aminotransferase (ALT), insulin-like growth factor-1 (IGF-1), glucose, insulin, glucagon, and cortisol.
References

[1]. Wang XX, et al. Effects of octreotide on hepatic glycogenesis in rats with high fat diet?induced obesity. Mol Med Rep. 2017 Jul;16(1):109-118

[2]. Kugita M, et al. Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease. PLoS One. 2017 May 18;12(5):e0177934.
Density 1.4±0.1 g/cm3
Boiling Point 1447.2±65.0 °C at 760 mmHg
Molecular Formula C49H66N10O10S2
Molecular Weight 1019.239
Flash Point 829.1±34.3 °C
Exact Mass 1018.440491
PSA 382.82000
LogP 0.77
Vapour Pressure 0.0±0.3 mmHg at 25°C
Index of Refraction 1.673
Storage condition −20°C
Water Solubility H2O: soluble
Personal Protective Equipment Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
RIDADR NONH for all modes of transport
HS Code 3004909090
Precursor  1

DownStream  0

HS Code 3004909090

Chemsrc provides CAS#:83150-76-9 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 83150-76-9 | Chemsrc address: https://www.chemsrc.com/en/baike/243770.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved